Top Injectable Manufacturer in Burundi – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 9 hours ago
- 9 min read
Last Updated: August 17, 2026
TL;DR: Burundi's pharmaceutical sector is regulated by the Autorité Burundaise de Régulation des Médicaments à usage humain et des Aliments (ABREMA), created under Decree No. 100/039 of February 2021 and supervised by the Ministry of Public Health, which reviews EAC-harmonized Common Technical Document dossiers submitted in French and issues an Autorisation de Mise sur le Marché (AMM) under Ministerial Ordinance N°630/991 of August 2023. Burundi's regulator has publicly placed itself at WHO Global Benchmarking Tool Maturity Level 1, and while Burundi has been a Hague Apostille Convention member since 2015 — meaning Indian certificates carry legal apostille recognition rather than strictly requiring full consular legalization — manufacturers should still confirm current administrative practice with ABREMA before relying on that route for a specific dossier. Manufacturers typically work through a locally licensed wholesale distributor to import and register products. Demand is shaped by one of the heaviest malaria burdens in the world (an estimated 4.4 million cases in 2024 against a population at risk of just over 14 million, following epidemics in 2017 and 2019 that killed thousands), a maternal mortality rate historically among the highest globally, and a public health system operating under real foreign-currency constraints. Farbe Firma's WHO-GMP certified, ISO Class 5 facility in Gujarat, India, with 100+ injectable products exported to over 30 countries, is built to support CAMEBU and Burundi's importers through this demanding, high-need market.
Key Takeaways
Regulatory pathway: ABREMA (Autorité Burundaise de Régulation des Médicaments à usage humain et des Aliments), created under Decree No. 100/039 (26 February 2021) and supervised by the Ministry of Public Health, reviews EAC-harmonized CTD dossiers — submitted in French — and issues the Autorisation de Mise sur le Marché (AMM) under Ministerial Ordinance N°630/991 (9 August 2023). Burundi has been an East African Community member since 2007 and participates in the EAC Medicines Regulatory Harmonization joint assessment procedure alongside Kenya, Tanzania, Rwanda and Uganda.
WHO maturity and legalization: ABREMA's own leadership has publicly placed the authority at WHO Global Benchmarking Tool Maturity Level 1, a genuinely earlier stage than several neighboring regulators, so we build every dossier to full CTD convention rather than a minimal checklist. On legalization, Burundi has been a Hague Apostille Convention member since February 2015 and India since 2005 with no objection recorded between the two countries, so Indian certificates carry legal apostille standing — though we recommend confirming current ABREMA administrative practice per dossier given the gap that can exist between treaty status and in-country processing.
Local distribution and language: Manufacturers typically operate through a locally licensed wholesale distributor-importer to register and bring products to market, since ABREMA's import process runs through the ASYCUDA electronic single-window system with physical inspection on arrival. French is the working language of Burundi's pharmaceutical regulatory system in practice, and Farbe Firma prepares dossiers, labels and package inserts in French for ABREMA submission even though English gained official-language status in 2014.
Demand drivers: Burundi recorded an estimated 4.4 million malaria cases in 2024 against a population at risk of roughly 14 million — among the highest burdens in the world — following major epidemics in 2017 and 2019 that the United Nations called one of the world's worst malaria crises of that year; maternal mortality has historically run among the highest rates globally; and recurring cholera and a 2024-2025 mpox outbreak keep outbreak-response and supportive-care injectables a standing Ministry of Public Health priority.
Introduction: Why an Injectable Manufacturer in Burundi Must Meet Global Standards
Burundi's pharmaceutical regulatory system is still young. The Autorité Burundaise de Régulation des Médicaments à usage humain et des Aliments, created under Decree No. 100/039 in February 2021 and operating under the Ministry of Public Health, took over registration functions previously handled inside the ministry's own pharmacy department, and now reviews EAC-harmonized Common Technical Document dossiers — submitted in French — under a marketing-authorization process formalized by Ministerial Ordinance N°630/991 in August 2023. ABREMA's own leadership has publicly described the authority as being at an early stage on the WHO Global Benchmarking Tool, and Burundi's regulator is not currently a PIC/S member, applicant or pre-applicant. For an injectable manufacturer in Burundi building a durable supply relationship, that stage of development matters less than it might seem: Burundi's participation in the East African Community's regional harmonization program means a technical file built to genuine CTD convention — the same standard used across Kenya, Tanzania, Rwanda and Uganda — transfers efficiently into Burundi's own review, giving ABREMA a stronger dossier to work from as its own capacity continues to build.
That regulatory picture sits against genuinely severe health needs. Burundi recorded an estimated 4.4 million malaria cases in 2024 against a population at risk of just over 14 million people — one of the heaviest malaria burdens anywhere in the world — a legacy of epidemics in 2017 and 2019 that the United Nations described as one of the world's worst malaria crises of that year; maternal mortality has historically run among the highest rates globally; and the health system continues to manage recurring cholera outbreaks and a 2024-2025 mpox outbreak alongside chronic foreign-exchange pressure that constrains what CAMEBU and private importers can bring in at any given time. Burundi imports the great majority of the pharmaceutical products it consumes, so its public and private supply chain depends on overseas manufacturers who can document real manufacturing discipline rather than simply claim it. Farbe Firma, a WHO-GMP certified sterile injectable manufacturer from Gujarat, India, is built for precisely that reliability.
What Sets a World-Class Injectable Manufacturer in Burundi Apart
An injectable manufacturer in Burundi is judged on whether its quality data can support a still-developing regulator's review, not on how polished a submission looks on the surface. That means validated aseptic filling under ISO Class 5 conditions, environmental and personnel monitoring trends built from genuine production history, container-closure integrity data, and process validation demonstrated across multiple commercial-scale batches rather than a single development run. Farbe Firma's Gujarat facility was built around exactly this documentation discipline — dedicated sterile filling lines and batch records structured for full CTD submission from the outset — which matters in a market where dossier completeness, rather than local reviewer capacity, is often the limiting factor on registration speed.
Getting the pathway right matters as much as getting the manufacturing right. Manufacturers typically work through a locally licensed wholesale distributor-importer to register and bring products into Burundi, since import authorizations move through the ASYCUDA electronic single-window system with physical inspection by ABREMA officers on arrival. On legalization, Burundi has been a Hague Apostille Convention member since February 2015, and because India has also been a member since 2005 with no objection recorded between the two countries, Indian certificates of pharmaceutical product and GMP certificates carry legal apostille standing rather than strictly requiring full consular legalization — though we build in time to confirm current ABREMA administrative practice for each specific dossier, since treaty status and in-country processing habits do not always move in lockstep. Every dossier, label and package insert is prepared in French, the working language of Burundi's regulatory system in practice.
Quality Systems Behind Every Batch We Ship to Burundi
Every batch destined for Burundi clears a full analytical panel before it leaves Gujarat: identity, assay and related-substances testing by HPLC or GC referenced against USP, BP, IP or EP monographs as applicable; Karl Fischer titration for water content in lyophilized and moisture-sensitive presentations; sterility and bacterial endotoxin (LAL) testing on every parenteral lot; and particulate matter, pH, osmolality and fill-volume verification on finished units. This is exactly the primary data a full CTD module-3 submission is built to interrogate, so the certificate of analysis a Burundian importer or ABREMA reviewer receives reflects the same evidence base international regulators are trained to expect, not a summarized claim.
Burundi's landlocked geography and dependence on regional transit corridors shape how Farbe Firma plans every shipment: stability data is held to ICH Q1A(R2) long-term and accelerated conditions with ICH Q1B photostability data for light-sensitive actives, while logistics realistically route via the Port of Dar es Salaam, Tanzania on the Central Corridor — the main artery for over 80% of Burundi's trade — or the longer Northern Corridor via Mombasa, Kenya, with onward transport to Bujumbura by road or, increasingly, via the Lake Tanganyika ferry route that African Development Bank financing is working to modernize. For urgent or temperature-critical consignments, air freight through Bujumbura International Airport via Nairobi, Addis Ababa or Brussels offers a materially faster alternative to ocean transit.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Burundi for Global Buyers
Farbe Firma's portfolio of more than 100 sterile injectable products lines up closely with what Burundi's health system actually needs. Injectable artesunate and other antimalarials respond to a malaria burden of an estimated 4.4 million cases in 2024, one of the heaviest caseloads of any country worldwide; oxytocics and emergency obstetric injectables address a maternal mortality rate that has historically run among the highest globally; and broad-spectrum injectable antibiotics and IV fluids support a health system that continues to manage recurring cholera outbreaks and, most recently, mpox. Cardiovascular, anti-diabetic and other supportive-care injectables round out a portfolio built for a country still working to build out its chronic-disease response alongside a dominant infectious-disease burden.
Beyond finished-product supply, Farbe Firma operates as a full CDMO partner: contract manufacturing, formulation support and private-label injectable programs for importers building their own Burundian brand portfolios. Every registration package we assemble includes the WHO-format Certificate of Pharmaceutical Product and GMP certificate, apostilled through India's Ministry of External Affairs to match Burundi's Hague Convention membership, plus French-language dossiers and package inserts prepared to EAC-harmonized CTD conventions for ABREMA's review. Where a buyer is pursuing CAMEBU or donor-funded tender business — the World Bank's US$40 million foreign-currency trade facility approved in January 2024 to help Burundian banks cover strategic imports including pharmaceuticals, the Global Fund's roughly US$16 million 2024 malaria grant, and Gavi's March 2025 malaria vaccine rollout are all actively shaping procurement — we also prepare tender-specific documentation and pricing structures aligned to those programs' realities, including the currency-access constraints that shape how and when Burundian buyers can actually pay for imports.
The honest advice we give Burundi-bound clients is that documentation completeness and payment/logistics planning decide most launch timelines more than any other factor: a French translation left incomplete stalls an ABREMA submission, and Burundi's foreign-exchange environment — where the gap between official and parallel exchange rates has run more than twofold in recent years — means financing and currency-access planning deserve the same attention as the regulatory dossier itself. On logistics, we plan production and shipping around a realistic multi-week transit window via Dar es Salaam or Mombasa, with air freight via Bujumbura as a faster option for time-sensitive consignments, rather than assuming an unusually fast direct route.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified injectable manufacturer for Burundi?
Yes. Farbe Firma operates a WHO-GMP certified sterile injectable facility in Gujarat, India, with aseptic filling under ISO Class 5 conditions. The facility produces more than 100 injectable products — including antimalarials, antibiotics, oxytocics and IV fluids — and exports to more than 30 countries. That status underpins the Certificate of Pharmaceutical Product and GMP certificate accompanying every CTD-format dossier we prepare for Burundi's ABREMA.
How does injectable product registration actually work in Burundi?
Registration runs through the Autorité Burundaise de Régulation des Médicaments à usage humain et des Aliments (ABREMA), created under Decree No. 100/039 of February 2021 and supervised by the Ministry of Public Health. ABREMA reviews EAC-harmonized Common Technical Document dossiers, submitted in French, and issues an Autorisation de Mise sur le Marché (AMM) under Ministerial Ordinance N°630/991 of August 2023. Import authorizations are processed through the ASYCUDA electronic single-window system with physical inspection on arrival.
Do we need a local partner or agent to sell injectables in Burundi?
In practice, yes. While there is no single statute making this an explicit legal requirement, ABREMA's own registration and import-inspection process, run through locally resident entities, means manufacturers typically operate through a locally licensed wholesale distributor-importer rather than registering directly. Farbe Firma works with distributors who already hold this local standing.
Which injectables are in strongest demand in Burundi?
Demand tracks Burundi's health profile closely. An estimated 4.4 million malaria cases in 2024 — among the highest burdens in the world relative to population — sustain strong demand for injectable antimalarials, including artesunate for severe cases; a maternal mortality rate that has historically run among the highest globally keeps oxytocics and emergency obstetric injectables in steady demand; and recurring cholera and mpox outbreaks keep supportive-care antibiotic injectables and IV fluids a standing priority. CAMEBU is the country's central public-sector medicines and medical-supplies purchasing body.
What documentation and logistics considerations matter most for a Burundi launch?
Three things stand out. First, Burundi has been a Hague Apostille Convention member since 2015, so Indian certificates carry legal apostille standing, though current ABREMA administrative practice is worth confirming per dossier. Second, every dossier, label and package insert should be prepared in French, the working language of Burundi's regulatory system in practice. Third, Burundi's foreign-exchange constraints — a substantial gap between official and parallel exchange rates — make payment and currency-access planning as important as the registration timeline itself. On logistics, shipments typically route via the Port of Dar es Salaam or Mombasa, with air freight via Bujumbura International Airport available for urgent consignments.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments